

SOHO-France - Cohort of Schizophrenic Patients Receiving Antipsychotic Drugs

Head :Gasquet Isabelle

Last update : 09/05/2017 | Version : 1 | ID : 73154

General

Identification

| | |
|---------------|--|
| Detailed name | Cohort of Schizophrenic Patients Receiving Antipsychotic Drugs |
|---------------|--|

| | |
|-----------------|-------------|
| Sign or acronym | SOHO-France |
|-----------------|-------------|

| | |
|--|------|
| CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | CNIL |
|--|------|

General Aspects

| | |
|--------------|--|
| Medical area | Disability/handicap Psychology and psychiatry |
|--------------|--|

| | |
|---------------------|---------------|
| Pathology (details) | Schizophrenia |
|---------------------|---------------|

| | |
|---------------------|---|
| Health determinants | Genetic Iatrogenic Lifestyle and behavior Medicine |
|---------------------|---|

| | |
|----------|---|
| Keywords | antipsychotic, remission, schizophrenia, relapse, treatment |
|----------|---|

Scientific investigator(s) (Contact)

| | |
|----------------------|---------|
| Name of the director | Gasquet |
|----------------------|---------|

| | |
|---------|----------|
| Surname | Isabelle |
|---------|----------|

| | |
|-------|----------------------|
| Phone | +33 (0)1 40 27 31 85 |
|-------|----------------------|

| | |
|-------|--------------------------------------|
| Email | isabelle.gasquet@pbr.ap-hop-paris.fr |
|-------|--------------------------------------|

| | |
|--------------|------------------------|
| Organization | Paris Public Hospitals |
|--------------|------------------------|

Collaborations

| Funding | |
|--|--|
| Funding status | Private |
| Details | Lilly France pharmaceutical laboratory |
| Governance of the database | |
| Sponsor(s) or organisation(s) responsible | Assistance publique?hôpitaux de Paris |
| Organisation status | Public |
| Additional contact | |
| Main features | |
| Type of database | |
| Type of database | Study databases |
| Study databases (details) | Cohort study |
| Database recruitment is carried out by an intermediary | A selection of health care professionals |
| Database recruitment is is made on the basis of: | Medication(s) taken |
| Database recruitment is carried out as part of an interventional study | No |
| Additional information regarding sample selection. | Patients were recruited by psychiatrists drawn from the LOGIMED (IMS Health) and TVF (CEGEDIM) sampling frame with layering according to activity type (private versus hospital practice or mixed) and area of practice. Each psychiatrist must recruit four patients consecutively: two patients receiving olanzapine and two patients receiving an anti-psychotic prescribed at the discretion of the treating psychiatrist from available treatment (risperidone, amisulpride, clozapine, typical oral antipsychotics and intramuscular, long-acting medication). |
| Database objective | |
| Main objective | To provide information on patients monitored as outpatients, regardless of antipsychotic treatment received and to provide answers, especially regarding treatment adherence and remission rates, as well as relapse rates over a three-year |

monitoring period.

Inclusion criteria Schizophrenic adult patients monitored as outpatients and randomly recruited by psychiatrists.

Population type

Age Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)

Population covered Sick population

Gender Male
Woman

Geography area National

Detail of the geography area France

Data collection

Dates

Date of first collection (YYYY or MM/YYYY) 2001

Date of last collection (YYYY or MM/YYYY) 2005

Size of the database

Size of the database (number of individuals) [500-1000[individuals

Details of the number of individuals 964

Data

Database activity Data collection completed

Type of data collected Clinical data
Declarative data

Clinical data (detail) Direct physical measures

Details of collected clinical data History of illness, previous and ongoing treatments, symptomatology (Clinical Global Impression ?

Schizophrenia [CGI-SCH] scale) and a Visual Analogue Scale [VAS]). Clinical severity was measured by the CGI-SCH scale.

Declarative data (detail)

Face to face interview

Details of collected declarative data

Demographic data, quality of life (EuroQol scale of five items [EQ-5D]; addictive comorbidities in the form of simple questions on past and current use of illicit substances and alcohol; social status (accommodation type, type of work activity, number of social activities, etc.)

Presence of a biobank

No

Health parameters studied

Health care consumption and services

Care consumption (detail)

Medicines consumption

Procedures

Participant monitoring

Yes

Details on monitoring of participants

Follow-up at three and six months then every six months for three years.

Links to administrative sources

No

Promotion and access

Promotion

Link to the document

<http://www.ncbi.nlm.nih.gov/pubmed/19162420>

Access

Terms of data access (charter for data provision, format of data, availability delay)

Contact the scientist in charge.

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only